Prof. Ciechanover received the Nobel Prize in Chemistry for the discovery of ubiquitin-mediated protein degradation. In this discovery, he provided a key to understanding the ubiquitin system and paved the way for the development of drugs to prevent and treat certain illnesses. He has made a great contribution to the understanding of the mechanism of intracellular processes. Prof. Ciechanover has accompanied Carmel Diagnostics (and its predecessor, Lumitest) since 2003, and advises the company on strategic subjects, helping management to set development directions, to determine and focus on specific applications, and to position the company in the scientific world.
Prof. Reznick is a global expert in oxidative stress research and the President of the Israeli Society for Oxygen and Free Radicals Research. Prof. Reznick’s research group is involved in oxidative stress with special regard to muscle immobilization and aging, as well as cigarette- and smoke-related damage. His main research projects include the use of ThermoChemiLuminescence (TCL) to detect biological oxidation. Prof. Reznick is a Lecturer at the University of Haifa, Department of Gerontology, as well as an Associate Professor at the Technion Israel Institute of Technology. He received his PhD in Biochemistry from Florida State University.
Prof. Dirnfeld has been the president of the Israeli Fertility Society (IFS). She is Head of the Division of Reproductive Endocrinology and IDF at the Carmel Medical Center and a member of the Faculty of Medicine at the Technion Israel Institute of Technology. Prof. Dirnfeld is the National Committee Representative to the ESHRE in Europe. She graduated with an MD from the Technion Israel Institute of Technology. Prof. Dirnfeld was Board Certified in obstetrics and gynaecology following her residency at the Free University of Brussels and Carmel Medical Centre. She serves as Carmel’s fertility expert and advisor on clinical issues regarding women’s health.
Dr. Zofnat Wiener-Megnazi is an expert physician in obstetrics, gynecology, and fertility with vast experience in IVF treatment. She is Manager of the sperm bank in the unit and a leading force in our research activity. Dr. Wiener-Megnazi was principal investigator of our “proof of concept” study in embryo selection application and is responsible for four articles on the fertility application of oxidative stress as a biomarker. She graduated in Medicine at the Hebrew University, Jerusalem, Israel. Dr. Wiener-Megnazi is teaching in the medical school of the Technion and guides students in their research.
Tzali Cnaani has a proven track record in all facets of leading R&D and businesses, from inception to fund raising, product strategy,operations and sales management. Previously, Mr. Cnaani was CEO of Lumitest, which developed a unique medical device to measure oxidative stress in biological fluids, establishing the technology through cooperation with medical centers and academia. Prior to that, he was CEO of SAE Afikim (Afimilk), a world leader in computerized dairy management systems. Mr. Cnaani was EVP and member of the board of directors of Gambit Computer Communication. He holds a B.Sc. degree in physics from the Technion Israel Institute of Technology.
Dr. Sergei Shnizer is the inventor of TCL technology and the first to apply it to medicine. Specializing in Anesthesiology and Intensive Care Medicine, he developed an interest in the effect and mechanisms of free radicals in critically ill patients. Dr. Shnizer was also a co-founder of SPM Ltd. (now OZ Recovery Technologies), which developed a device for treatment of diabetes wounds using ozone. Prior to immigrating to Israel, he spent 15 years at Botkin Hospital in Moscow in the Department of Emergency Medicine and Hyperbaric Oxygen as Senior Physician. Dr. Shnizer’s Ph.D. thesis covered “Using Free Radical Activity Tests in Intensive Care Units.” He has published over 30 articles in peer-reviewed journals.
Mr. Shavit is an accomplished Senior Technology Executive with a proven track record for building, leading, and commercializing world-class medical devices. He has held positions as VP of R&D at ThermoGenesis Corp. (California, USA), MediVision, SAE Afikim, Trig Medical, and AFP Imaging, and has been responsible forproduct development and commercialization. Mr. Shavit earned his M.Sc. and B.Sc. degrees in electronics from the Poly-NYU University and is a co-author of several patents in medical devices and imaging and in telecommunication systems.